registered under the Securities Act of 1933, as amended (the "Securities
Act"), and may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements.
PharmAthene has agreed to file a registration statement under the
Securities Act to register the shares of common stock to be issued at
closing and upon any exercise of the warrants for public resale from time
to time in the future. There can be no assurances that the registration
statement will be declared effective. The information contained in this
press release does not constitute an offer for the sale of any securities.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States
and its allies by developing and commercializing medical countermeasures
against biological and chemical weapons. PharmAthene's lead product
development programs include:
-- SparVax(TM) - a second generation recombinant protective antigen (rPA)
-- Third generation rPA anthrax vaccine
-- Valortim(R) - a fully human monoclonal antibody for the prevention and
treatment of anthrax infection
-- Protexia(R) - a novel bioscavenger for the prevention and treatment of
morbidity and mortality associated with exposure to chemical nerve
-- RypVax(TM) - a recombinant dual antigen vaccine for plague
For more information about PharmAthene, please visit
About Panacea Biotec Ltd.
Panacea Biotec is an Indian research-based health management company
with established research, manufacturing and marketing capabilities.
Panacea Biotec's product portfolio includes innovative prescription
products in important therapeutic areas such as pain management, diabetes
management, renal-disease management, anti-osteoporosis, anti-tubercualar,
gastro-intestinal cPage: 1 2 3 4 5 Related biology technology :1
. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.2
. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court3
. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services4
. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA5
. PharmAthene to Present at the BIO CEO & Investor Conference 20086
. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations7
. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 20088
. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference9
. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia10
. PharmAthene to Delay Release of Full Year 2007 Financial Results11
. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008